Ming Yan sold $121k of CTKB
Chief Technology Officer at Cytek Biosciences, Inc.. 20,000 shares at an average of $6.03, traded Nov 20, 2023, filed Nov 21, 2023.
Score components
- +15RoleOfficer
- +10Trade size$121k at market
- 0Share of holdings soldSold 0.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +48.9%, 3m +35.4%, 6m -2.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-23-056353, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2023 | MOption exercise Common Stock | +1,981 | - | - | 7,777,943 | Nov 21, 2023 |
| Nov 18, 2023 | FTax withholding Common Stock | -772 | $5.98 | $4,617 | 7,777,171 | Nov 21, 2023 |
| Nov 18, 2023 | MOption exercise Common Stock | +7,363 | - | - | 7,784,534 | Nov 21, 2023 |
| Nov 18, 2023 | FTax withholding Common Stock | -2,431 | $5.98 | $15k | 7,782,103 | Nov 21, 2023 |
| Nov 20, 2023 | SOpen-market sale Common Stock10b5-1 | -20,000 | $6.03 | $121k | 7,762,103 | Nov 21, 2023 |
| Nov 18, 2023 | MOption exercise Restricted Stock Unitsderivative | -1,981 | $0.00 | $0 | 17,180 | Nov 21, 2023 |
| Nov 18, 2023 | MOption exercise Restricted Stock Unitsderivative | -7,363 | $0.00 | $0 | 98,179 | Nov 21, 2023 |
Related signals
Other insiders at Cytek Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | CTKBbuy Cytek Biosciences, Inc. | William D. McCombe Chief Financial Officer | $97k 35,000 shares | +169% | |
| 15Weak | Cytek Biosciences, Inc. | Patrik Jeanmonod Chief Financial Officer | $29k 3,000 shares | -3% | |
| 15Weak | Cytek Biosciences, Inc. | Ming Yan Chief Technology Officer | $189k 20,000 shares | -0% | |
| 10Weak | Cytek Biosciences, Inc. | Patrik Jeanmonod Chief Financial Officer | $21k 3,000 shares | -3% | |
| 29Weak | Cytek Biosciences, Inc. | Wenbin Jiang President and CEO | $87k 20,000 shares | -0% | |
| 17Weak | Cytek Biosciences, Inc. | Patrik Jeanmonod Chief Financial Officer | $14k 3,000 shares | -3% | |
| 20Weak | Cytek Biosciences, Inc. | Ming Yan Chief Technology Officer | $96k 20,000 shares | -0% | |
| 23Weak | Cytek Biosciences, Inc. | Wenbin Jiang President and CEO | $107k 20,000 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.